Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study

Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of immune checkpoint inhibitors in patients with stage III and IV AM and compare them to cutaneous melanoma (CM). We included patients wi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2022-05, Vol.167, p.70-80
Main Authors: van Not, Olivier J., de Meza, Melissa M., van den Eertwegh, Alfons J.M., Haanen, John B., Blank, Christian U., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., van Breeschoten, Jesper, de Groot, Jan-Willem B., Hospers, Geke A.P., Ismail, Rawa K., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Stevense-den Boer, Marion A.M., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Bonenkamp, Han J., Boers-Sonderen, Marye J., Blokx, Willeke A.M., Wouters, Michel W.J.M., Suijkerbuijk, Karijn P.M.
Format: Article
Language:English
Subjects:
Apoptosis
Cell death
Cohort analysis
Cohort Studies
Humans
Immune checkpoint
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Inhibitors
Ipilimumab - therapeutic use
Medical prognosis
Melanoma
Melanoma - mortality
Melanoma, Cutaneous Malignant
Nivolumab - adverse effects
Patients
PD-1 protein
Prospective Studies
Response
Response rates
Skin Neoplasms - drug therapy
Skin Neoplasms - immunology
Statistical models
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of immune checkpoint inhibitors in patients with stage III and IV AM and compare them to cutaneous melanoma (CM). We included patients with advanced AM and CM treated with first-line anti-programmed cell death (PD)-1 monotherapy or ipilimumab-nivolumab registered in the prospective nationwide Dutch Melanoma Treatment Registry. Objective response rates, progression-free survival (PFS) and overall survival (OS) were calculated. A Cox proportional hazard model was used to assess the prognostic factors with PFS and OS. In total, 2058 patients (88 AM and 1970 CM) with advanced melanoma were included. First-line objective response rates were 34% for AM versus 54% for CM in the advanced anti-PD-1 cohort and 33% for AM versus 53% for CM in the advanced ipilimumab-nivolumab cohort. The Median PFS was significantly shorter for anti-PD-1 treated AM patients (3.1 months; 95%CI: 2.8–5.6) than patients with CM (10.1 months; 95%CI: 8.5–12.2) (P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2022.02.026